5326122025-10-012025-12-315326122025-04-012025-12-315326122025-10-012025-12-31in-capmkt:OtherExpenses1Member5326122025-10-012025-12-31in-capmkt:OtherExpenses2Member5326122025-04-012025-12-31in-capmkt:OtherExpenses1Member5326122025-04-012025-12-31in-capmkt:OtherExpenses2Member5326122025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15326122025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares532612INDOCONOTLISTEDINE873D01024INDOCO REMEDIES LIMITEDMain BoardEquity2025-04-012026-03-312026-02-032026-01-16INRLakhsQuarterlyThird quarterSingle segmentPHARMACEUTICALS2026-02-0311:05:002026-02-0311:50:00Not applicable2025-10-012025-12-31UnauditedConsolidated445360000098000004463400000978900000329900000-104600000106030000025640000032010000018740000004715000000-251600000-61500000-313100000100000-18700000-186000000-2945000000000-294500000-12600000-307100000-2979000003400000-31050000034000001845000002-3.2-3.1900-3.2-3.191.The unaudited Consolidated Results for the quarter and Nine months ended 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Director of the Company at its meeting held on 03rd February, 2026. The Statutory Auditors have expressed an Unmodified Audit Opinion on these unaudited Consolidated Financial Results. <BR> 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. <BR> 3.The company has only one primary reportable segment of activity, namely, Pharmaceuticals. <BR> <BR> 4.Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: <BR> <BR> Net Sales Quarter Quarter Quarter Nine months Nine months Year <BR> & Ended Ended Ended Ended Ended Ended <BR> Income from 31.12.2025 30.09.2025 31.12.2024 31.12.2025 31.12.2024 31.03.2025 <BR> Operation (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) <BR> <BR> <BR> India 29,544 30,370 28,162 87,698 82,853 1.09,039 <BR> Outside India 13,890 16,813 12,083 46,006 42,887 55,090 <BR> Total 43,434 47,183 40,245 1,33,704 1,25,740 1,64,129 <BR> <BR> <BR> 5. The Consolidated Financial Results includes the Results of the following Companies <BR> ---------------------------------------------------------------------------------------------------------------------------------- <BR> Name of theCompany % of shareholding Consolidated as <BR> --------------------------------------------------------------------------------------------------------------------------------- <BR> Xtend Industrial Designers & Engineers Pvt Ltd 100.00 Subsidiary <BR> Indoco Remedies Czech SRO 100.00 Subsidiary <BR> Indoco Remedies UK Ltd 100.00 Subsidiary <BR> Warren Remedies Private Limited 100.00 Subsidiary <BR> FPP Holding Company , LLC 85.00 Subsidiary <BR> ================================================================================ <BR> 6.The statutory auditors of the Company have carried out limited review of the financial results for the quarter ended 31st December, 2025. <BR> 7. (*) Exceptional items includes : (a) Consideration received Rs. 253 lakhs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company, <BR> (b) Loss amounting to Rs. 213 lakhs on sale and leaseback of its Non current Assets, and, <BR> (c) Impact of past period employee benefit liability amounting to Rs. 708 lakhs due to implementation of the New Labour Codes. <BR> 8. Effective 21" November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Group has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs. 708 lakhs primarily arising due to change in definition of "wages" for employees and contract labours. Considering the materiality and nonrecurring nature of this impact, the Group has presented such incremental impact under 'Exceptional Item" in the consolidated financial results for the quarter and nine months ended 31st December, 2025. The Group continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. <BR> 2025-04-012025-12-31UnauditedConsolidated13697100000337000001373080000031641000001110400000-2672000003162800000763200000939600000560600000014478900000-748100000-66800000-814900000600000-65500000-649000000-7500000000000-75000000011700000-738300000-735000000-15000000-723300000-150000001845000002-8.14-8.1300-8.14-8.13RESEARCH & DEVELOPMENT EXPENSES183100000OTHER EXPENSES1690900000RESEARCH & DEVELOPMENT EXPENSES617800000OTHER EXPENSES4988200000ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT & LOSS-7700000-7700000ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT & LOSS-23000000-23000000-1900000-5700000ITEMS THAT MAY BE RECLASSIFIED TO PROFIT & LOSS-4800000-4800000ITEMS THAT MAY BE RECLASSIFIED TO PROFIT & LOSS4040000040400000200000011400000-1260000011700000